Clearmind Medicine (CMND) announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind’s US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Clearmind, Gifford served as Chief of Global Impact at Psyence BioMed (PBM).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
- Clearmind Medicine enrolls last patient for first cohort of CMND-100 trial
- SciSparc, Clearmind announce publication of U.S. patent application
- Clearmind announces publication of U.S. patent application on binge behavior
- Psychedelic: Exclusive talk with ibogaine clinic Beond